Memphasys nears trial completion

Memphasys (ASX:MEM), a leader in reproductive biotechnology, announced significant advancements in its Felix™ System clinical trials. The company has nearly completed patient recruitment, reaching 95%, and expects to finish by year's end. The trials, conducted in partnership with Monash IVF Group Ltd, are crucial for regulatory submissions and market entry.

Overview and future outlook

Memphasys is making progress towards completing its clinical trials for the Felix™ System, a breakthrough in sperm separation technology for assisted reproduction. With 95% of patient recruitment completed, the trial is expected to end by the calendar year's close. The company plans to use the trial data to secure CE mark registration, facilitating quicker entry into the European market, followed by expansions into India and Australia. Positive results are anticipated to enhance distributor, partner, and investor discussions, furthering Memphasys’ growth and commercial strategies. The Felix™ System, combining electrophoresis and size exclusion membranes, aims to outperform traditional sperm selection methods, paving the way for its acceptance in fertility clinics globally.

Executive insights on trial progress

The company is committed to fast-tracking the Felix™ System's clinical validation and commercial growth through a focused CE mark strategy.